Drug Profile
Melanoma vaccine - Pierre Fabre
Alternative Names: F-50040; P40/ELA; Project F 50 040Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Ludwig Institute for Cancer Research
- Developer Pierre Fabre
- Class Cancer vaccines; Peptides; Proteins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Malignant melanoma
Most Recent Events
- 12 Mar 2008 Disconintued - Phase-I for Malignant melanoma in France (Parenteral)
- 28 Oct 2005 Phase-I clinical trials in Malignant melanoma in France (unspecified route)
- 11 Jul 2001 Preclinical development for Malignant melanoma in France (Unknown route)